Concert Pharmaceuticals

Concert’s CTP-656 receives FDA Orphan designation for cystic fibrosis

Monday, January 23, 2017

Concert Pharmaceuticals has announced that the FDA has granted Orphan Drug designation for CTP-656, Concert’s next generation CFTR potentiator being developed for the treatment of cystic fibrosis. In December 2016, Concert initiated a phase II trial in the U.S. evaluating CTP-656 in cystic fibrosis patients with gating mutations. Topline results from the phase II trial are expected by year-end 2017.

[Read More]

PureTech expands scientific advisory board team and advisory group

Friday, July 8, 2016

PureTech Health, a cross-disciplinary biotech company developing novel medicines at the interface of the gut, brain and immune system, has announced the appointment of Feng Zhang, Ph.D., to its scientific advisory board (SAB). The company has also appointed Jeff Stevens, as vice president of Growth Strategy & Operations and has expanded its team of senior advisors to include Meghan Fitzgerald, DrPH, executive vice president of Corporate Strategy, M&A and Health Policy at Cardinal Health; Atul Pande, M.D., former senior vice president and head of Neurosciences at GlaxoSmithKline; and Philip J. Larsen, M.D., Ph.D., global head of Diabetes Research & Development at Sanofi.

[Read More]

Jazz, Concert partner to develop deuterium-modified sodium oxybate

Wednesday, February 27, 2013

Jazz Pharmaceuticals, an Irish specialty biopharmaceutical company focused on unmet medical needs, and Concert Pharmaceuticals, a Lexington, Mass.-based clinical stage biotechnology company, have signed an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert’s deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323.   

[Read More]